Amarillo Biosciences Licenses Low Dose Oral Interferon to Global Kinetics for Sale in Three Countries in SE Asia

AMARILLO, TX -- (MARKET WIRE) -- 10/20/05 -- Amarillo Biosciences, Inc.
(ABI) (OTC BB: AMAR) today announced that it had entered into a
licensing and supply agreement with Seattle-based Global Kinetics, Inc.
to provide low dose oral interferon for sale in Cambodia, Laos and
Vietnam.

Interest in the Company's low dose oral interferon has risen with
international concern about the potential of the current bird flu
outbreak to develop into a pandemic. Health care professionals agree
that the public is vulnerable to the pending influenza pandemic.
Effective vaccination for influenza is the goal of health officials.
However, no vaccine is yet available for the H5N1 virus (bird flu), and
the therapies that do exist, such as Tamiflu, are in limited supply
worldwide. Consequently, ABI and Global Kinetics are working together
to bring a promising new prevention and treatment option for influenza
to the developing world.

Global Kinetics (www.globalkinetics.net) intends to market ABI's low
dose oral interferon through a Cambodian company (Global Kinetics of
Cambodia). "Low-dose oral interferon represents an inexpensive,
non-toxic modulation of the immune system during, or before, influenza
infection. Our first purchase order is expected from the Kingdom of
Cambodia so a supply of oral interferon will be available in case bird
flu infects government personnel. Government officials in Cambodia have
reviewed the clinical observations made on thousands of influenza
patients in the former Soviet Union, Bulgaria, China, and Japan. These
studies indicate that significant clinical benefits occurred in
patients given low-dose interferon intranasally or orally during
natural outbreaks of influenza," said Global Kinetics President Jerry
Frasier. ABI President Joseph Cummins said, "We are pleased to be
working with Global Kinetics and look forward to a long lasting and
mutually beneficial relationship."

Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that
involve risks and uncertainties, including uncertainties related to
product development, uncertainties related to the need for regulatory
and other government approvals, dependence on proprietary technology,
uncertainty of market acceptance of oral interferon or the Company's
other product candidates and other risks detailed from time to time in
the Company's filings with the Securities and Exchange Commission. In
particular, see "Item 1. Description of Business" of the Company's Form
10-KSB for the year ended December 31, 2004.



Investor Relations:
Philippe Niemetz
WPH Consultants, Ltd.
Tel: 800-477-7570
Tel: 212-344-6464
Fax: 212-618-1276
e-mail: Email Contact

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: 806-376-1741 x 13
Fax: 806-376-9301
e-mail: Email Contact




20051020

.